Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies

World Journal of Gastroenterology

Volumn 21, Issue 11, 2015, Pages 3174-3183

  Gambhir, Sahil ^a   Vyas, Dinesh ^a   Hollis, Michael ^a   Aekka, Apporva ^a   Vyas, Arpita ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Gastrointestinal cancer; Inflammation; Nuclear factor kappa B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTIINFLAMMATORY AGENT; AUTACOID;

CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; ESOPHAGUS CANCER; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; ANIMAL; CELL TRANSFORMATION; COMPLICATION; GASTROINTESTINAL NEOPLASMS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL TRANSFORMATION, NEOPLASTIC; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NF-KAPPA B; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84925668843     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i11.3174     Document Type: Review

References (89)

1. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009;8:33-40 [PMID: 19116625 DOI: 10.1038/nrd2781]
2. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288 [PMID: 15145317 DOI: 10.1016/j.it.2004.03.008]
3. Vyas D, Robertson CM, Stromberg PE, Martin JR, Dunne WM, Houchen CW, Barrett TA, Ayala A, Perl M, Buchman TG, Coopersmith CM. Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine. Histol Histopathol 2007;22:623-630 [PMID: 17357092]
4. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310 [PMID: 12001991 DOI: 10.1038/nrc780]
5. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355-361 [PMID: 16673382 DOI: 10.1002/mc.20217]
6. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400 [PMID: 22435567 DOI: 10.1111/j.1600-065X.2012.01099.x]
7. Ditsworth D, Zong WX. NF-kappaB: key mediator of inflammationassociated cancer. Cancer Biol Ther 2004;3:1214-1216 [PMID: 15611628 DOI: 10.4161/cbt.3.12.1391]
8. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-149 [PMID: 8311838 DOI: 10.1016/0006-2952 (94) 90448-0]
9. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFFinduced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002;3:958-965 [PMID: 12352969 DOI: 10.1038/ni842]
10. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210 [PMID: 17640394 DOI: 10.1186/bcr1678]
11. Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, Saetta AA, Tsigris C, Rallis G, Vlasis K, Patsouris E. Expression of Nuclear Factor κB in Human Gastric Carcinoma: Relationship with I. Ba and Prognostic Significance. Virchows Archiv 2007;450:519-527 [PMID: 17429689 DOI: 10.1007/s00428-007-0396-5]
12. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 1995;11:999-1003 [PMID: 7675461]
13. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-3639 [PMID: 9199297]
14. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 1997;57:3032-3039 [PMID: 9230219]
15. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000;89:2274-2281 [PMID: 11147598 DOI: 10.1002/1097-0142]
16. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M, Fusco A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997;15:1987-1994 [PMID: 9365245 DOI: 10.1038/sj.onc.1201373]
17. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-127 [PMID: 9918209]
18. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dörken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-4347 [PMID: 8639794]
19. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999;93:3044-3052 [PMID: 10216101]
20. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-6830 [PMID: 17072330 DOI: 10.1038/sj.onc.1209942]
21. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446:475-482 [PMID: 15856292 DOI: 10.1007/s00428-005-1264-9]
22. Brown KD, Estefania Claudio, and Ulrich Siebenlist. The Roles of the Classical and Alternative Nuclear Factor-kappaB Pathways: Potential Implications for Autoimmunity and Rheumatoid Arthritis. Arthritis Research Therapy 2008;10:212 [PMID: 18771589 DOI: 10.1186/ar2457]
23. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-α target for prevention and treatment of cancer. Cancer Lett 2004;206:193-199 [PMID: 15013524 DOI: 10.1016/j.canlet.2003.08.029]
24. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296 [PMID: 15294155 DOI: 10.1016/j.cell.2004.07.013]
25. Kang MR, Kim MS, Kim SS, Ahn CH, Yoo NJ, Lee SH. NFkappaB signalling proteins p50/p105, p52/p100, RelA, and IKKepsilon are over-expressed in oesophageal squamous cell carcinomas. Pathology 2009;41:622-625 [PMID: 20001340 DOI: 10.3109/00313020903257756]
26. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227 [PMID: 11875461 DOI: 10.1038/ni0302-221]
27. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J, Gross V. Nuclear Factor. B Is Activated in Macrophages and Epithelial Cells of Inflamed Intestinal Mucosa. Gastroenterology 1998;115:357-369 [PMID: 9679041 DOI: 10.1016/S0016-5085 (98) 70202-1]
28. Zubair A, Frieri M. Role of nuclear factor-κB in breast and colorectal cancer. Curr Allergy Asthma Rep 2013;13:44-49 [PMID: 22956391 DOI: 10.1007/s11882-012-0300-5]
29. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Digest Dis Sci 2004;49:1075-1083 [PMID: 15387324]
30. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-2142 [PMID: 17522398 DOI: 10.1056/NEJMoa067208]
31. Gibson MK, Dhaliwal AS, Clemons NJ, Phillips WA, Dvorak K, Tong D, Law S, Pirchi ED, Räsänen J, Krasna MJ, Parikh K, Krishnadath KK, Chen Y, Griffiths L, Colleypriest BJ, Farrant JM, Tosh D, Das KM, Bajpai M. Barrett's esophagus: cancer and molecular biology. Ann N Y Acad Sci 2013;1300:296-314 [PMID: 24117650 DOI: 10.1111/nyas.12252]
32. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239:491-500 [PMID: 15024310 DOI: 10.1097/01. sla.0000118751.95179.c6]
33. Jenkins GJ, Harries K, Doak SH, Wilmes A, Griffiths AP, Baxter JN, Parry JM. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-323 [PMID: 14656946 DOI: 10.1152/ajpgi.00092.2011]
34. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-α new approach to cancer therapy. J Clin Invest 2005;115:2625-2632 [PMID: 16200195 DOI: 10.1172/JCI26322]
35. Hormi-Carver K, Zhang X, Zhang HY, Whitehead RH, Terada LS, Spechler SJ, Souza RF. Unlike Esophageal Squamous Cells, Barrett's Epithelial Cells Resist Apoptosis by Activating the Nuclear Factor-B Pathway. Cancer Res 2009;69:672-677 [PMID: 19147583 DOI: 10.1158/0008-5472. CAN-08-3703]
36. Jenkins GJ, Mikhail J, Alhamdani A, Brown TH, Caplin S, Manson JM, Bowden R, Toffazal N, Griffiths AP, Parry JM, Baxter JN. Immunohistochemical Study of Nuclear Factor-B Activity and Interleukin-8 Abundance in Oesophageal Adenocarcinoma; a Useful Strategy for Monitoring These Biomarkers. J Clin Pathol 2007;60:1232-237 [PMID: 17220207 DOI: 10.1136/jcp. 2006.043976]
37. O'Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, Keeling PW, Kelleher D, Reynolds JV. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in theesophagus. Am J Gastroenterol 2005;100:1257-1264 [PMID: 15929754 DOI: 10.1111/j.1572-0241.2005.41338.x]
38. Abdel-Latif M M M J, O'riordan M, Ravi N, Kelleher D, Reynolds JV. Activated Nuclear Factor-kappa B and Cytokine Profiles in the Esophagus Parallel Tumor Regression following Neoadjuvant Chemoradiotherapy. Dis Esoph 2005;18:246-252 [DOI: 10.1111/j.1442-2050.2005.00497.x]
39. Szachnowicz S, Cecconello I, Iriya K, Marson AG, Takeda FR, Gama-Rodrigues JJ. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background. Clinics (Sao Paulo) 2005;60:103-112 [PMID: 15880245]
40. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy Nuclear Factor-B Status, Chemoradiation Resistance, and Metastatic Progression in Esophageal Carcinoma. Mole Cancer Therap 2006;5:2844-850 [DOI: 10.1158/1535-7163. MCT-06-0351]
41. Wang F, He W, Fanghui P, Wang L, Fan Q. NF-κBP65 promotes invasion and metastasis of oesophageal squamous cell cancer by regulating matrix metalloproteinase-9 and epithelial-tomesenchymal transition. Cell Biol Int 2013;37:780-8 [PMID: 23504993 DOI: 10.1002/cbin. 10089]
42. Wang F, He W, Fanghui P, Wang L, Fan Q. NF-κBP65 promotes invasion and metastasis of oesophageal squamous cell cancer by regulating matrix metalloproteinase-9 and epithelial-tomesenchymal transition. Cell Biol Int 2013;37:780-788 [PMID: 23504993 DOI: 10.1136/gut.2004.047100]
43. Liu JF, Jamieson GG, Drew PA, Zhu GJ, Zhang SW, Zhu TN, Shan BE, Wang QZ. Aspirin Induces Apoptosis in Oesophageal Cancer Cells by Inhibiting the Pathway of NF-kappaB Downstream Regulation of Cyclooxygenase-2. ANZ J Surg 2005;75:1011-1016 [PMID: 16336399 DOI: 10.1111/j.1445-2197.2005.03596.x]
44. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003;13:107-114 [PMID: 12654254]
45. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. J Cell Biochem 2004;92:646-650 [PMID: 15211562 DOI: 10.1002/jcb.20080]
46. Li B, Li YY, Tsao SW, Cheung A L M. Targeting NF-B Signaling Pathway Suppresses Tumor Growth, Angiogenesis, and Metastasis of Human Esophageal Cancer. Mole Cancer Therap 2009;8:2635-2644 [PMID: 19723887 DOI: 10.1158/1535-7163. MCT-09-0162]
47. Li J, Wang K, Chen X, Meng H, Song M, Wang Y, Xu X, Bai Y. Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol Biol 2012;13:4 [PMID: 22292433 DOI: 10.1186/1471-2199-13-4]
48. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of Activated Transcription Factor Nuclear Factor B With Chemoradiation Resistance and Poor Outcome in Esophageal Carcinoma. J Clini Oncol 2006;24:748-754 [PMID: 16401681 DOI: 10.1200/JCO.2005.03.8810]
49. Tian F, Zang WD, Hou WH, Liu HT, Xue LX. Nuclear Factor-κB Signaling Pathway Constitutively Activated in EsophagealSquamous Cell Carcinoma Cell Lines and Inhibition of Growth of Cells by Small Interfering RNA. Acta Biochim Biophys Sin 2006;38:318-326 [PMID: 16680372 DOI: 10.1111/j.1349-7006.2011.02025.x]
50. Han JC, Kai-Li Zhang, Xiao-Yan Chen, Hai-Feng Jiang, Qing-You Kong, Yuan Sun, Mo-Li Wu, Lei Huang, Hong Li, and Jia Liu. Expression of Seven Gastric Cancer-associated Genes and Its Relevance for Wnt, NF-κB and Stat3 Signaling. Apmis 2007;115:1331-343 [PMID: 18184402 DOI: 10.1111/j.1600-0643.2007.00695.x]
51. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Jang JS, Kim MC, Kim KH, Kim SJ, Kim SG, Kim HJ.. Clinicopathologic Significance of Expression of Nuclear Factor-κB RelA and Its Target Gene Products in Gastric Cancer Patients. World J Gastroenterol 2012;18:4744 [PMID: 23002344 DOI: 10.3748/wjg.v18.i34.4744]
52. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37 [PMID: 11902583 DOI: 10.1038/nrc703]
53. Isomoto H, Mizuta Y, Miyazaki M, Takeshima F, Omagari K, Murase K, Nishiyama T, Inoue K, Murata I, Kohno S. Implication of NF-kappaB in Helicobacter pylori-associated gastritis. Am J Gastroenterol 2000;95:2768-2776 [PMID: 11051346 DOI: 10.1111/j.1572-0241.2000.02304.x]
54. Lamb A, Yang XD, Tsang Y H N, Li JD, Higashi H, Hatakeyama M, Peek RM, Blanke SR, Chen LF. Helicobacter Pylori CagA Activates NF-κB by Targeting TAK1 for TRAF6-mediated Lys 63 Ubiquitination. EMBO Rep 2009;10:1242-1249 [PMID: 19820695 DOI: 10.1038/embor.2009.210]
55. Kang DW, Hwang WC, Park MH, Ko GH, Ha WS, Kim KS, Lee YC, Choi KY, Min DS. Rebamipide Abolishes Helicobacter Pylori CagA-induced Phospholipase D1 Expression via Inhibition of NFκB and Suppresses Invasion of Gastric Cancer Cells. Oncogene 2012;32:3531-3542 [PMID: 22890316 DOI: 10.1038/onc.2012.358]
56. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with Helicobactor pylori cagA (+) infection. World J Gastroenterol 2004;10:491-496 [PMID: 14966904]
57. Wu LF, Pu Z, Feng J, Li G, Zheng Z, Shen W. The Ubiquitinproteasome Pathway and Enhanced Activity of NF-κB in Gastric Carcinoma. J Surg Oncol 2008;97:439-444 [PMID: 18163448 DOI: 10.1002/jso.20952]
58. Yu BC, Jiang XH, Fan XM, Lin M C M, Jiang SH, Lam SK, Kung HF. Suppression of RelA/p65 Nuclear Translocation Independent of IκB-α Degradation by Cyclooxygenase-2 Inhibitor in Gastric Cancer. Oncogene 2003;22:1189-197 [PMID: 12606945 DOI: 10.1038/sj.onc.1206234]
59. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-4142 [PMID: 11751513]
60. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong WK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P. Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer. PLoS Genetics 2009;5:e1000676 [PMID: 19798449 DOI: 10.1371/journal.pgen. 100067]
61. Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, Noshiro H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 2004;24:1071-1075 [PMID: 15154625]
62. Long YM, Ye S, Rong J, Xie WR. Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma. World J Gastroenterol 2008;14:4739-4744 [PMID: 18720533 DOI: 10.3748/wjg.14.4739]
63. Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997;113:1099-1109 [PMID: 9322504]
64. Yin Y, Si X, Gao Y, Gao L, Wang J. The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol Rep 2013;29:34-38 [PMID: 23117246 DOI: 10.3892/or.2012.2089]
65. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38:904-910 [PMID: 22651903 DOI: 10.1016/j.ctrv. 2012.04.007]
66. Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem 2002;277:46093-46100 [PMID: 12324457 DOI: 10.1074/jbc. M206603200]
67. Liu XJ, Chen ZF, Li HL, Hu ZN, Liu M, Tian AP, Zhao D, Wu J, Zhou YN, Qiao L. Interaction between cyclooxygenase-2, Snail, and E-cadherin in gastric cancer cells. World J Gastroenterol 2013;19:6265-6271 [PMID: 24115825 DOI: 10.3748/wjg.v19.i37.6265]
68. Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, Inoue H, Chen GH. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol 2005;11:3197-3203 [PMID: 15929167]
69. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102 [PMID: 9488582]
70. Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IB, Correia L, Fernandes A, Camilo ME, Rodrigues CM. NFkappaB and apoptosis in colorectal tumourigenesis. Eur J Clin Invest 2007;37:416-424 [PMID: 17461988 DOI: 10.1111/j.1365-2362.2007.01801.x]
71. Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon JH, Takiguchi S, Miyata H, Yamasaki M, Mori M, Doki Y. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011;8:39-47 [PMID: 21289336]
72. Lind D, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM, Mackay S. Nuclear Factor-κB Is Upregulated in Colorectal Cancer. Surgery 2001;130:363-369 [PMID: 11490372 DOI: 10.1093/abbs/gmt071]
73. Shanahan F. Review article: colitis-associated cancer - time for new strategies. Aliment Pharmacol Ther 2003;18 Suppl 2:6-9 [PMID: 12950414 DOI: 10.1046/j.1365-2036.18.s2.5.x]
74. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009;6:327-334 [PMID: 19887045 DOI: 10.1038/cmi.2009.43]
75. Grivennikov SI. Inflammation and colorectal cancer: colitisassociated neoplasia. Semin Immunopathol 2013;35:229-244 [PMID: 23161445 DOI: 10.1007/s00281-012-0352-6]
76. Vaiopoulos AG, Athanasoula KCh, Papavassiliou AG. NF-κB in colorectal cancer. J Mol Med (Berl) 2013;91:1029-1037 [PMID: 23636511 DOI: 10.1007/s00109-013-1045-x]
77. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F. Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 2009;115:4946-4958 [PMID: 19658179 DOI: 10.1002/cncr.24564]
78. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, Katano M. Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004;24:675-681 [PMID: 15161011]
79. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Omata M. Constitutive NF-B Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth. Clin Cancer Res 2009;15:2248-258 [PMID: 19276252 DOI: 10.1158/1078-0432. CCR-08-138]
80. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004;91:381-388 [PMID: 15188000 DOI: 10.1038/sj.bjc.6601913]
81. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 2003;88:1598-1604 [PMID: 12771929 DOI: 10.1038/sj.bjc.6600927]
82. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA, Tanaka N. Overexpression of the Wild-type P53 Gene Inhibits NF-κB Activity and Synergizes with Aspirin to Induce Apoptosis in Human Colon Cancer Cells. Oncogene 2000;19:726-736 [PMID: 10698490 DOI: 10.1038/sj.onc.1203383]
83. Maihöfner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NFkappaB in human colorectal cancer. Carcinogenesis 2003;24:665-671 [PMID: 12727794 DOI: 10.1093/carcin/bgg006]
84. Gan HT, Chen YQ, Ouyang Q. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J Gastroenterol Hepatol 2005;20:1016-1024 [PMID: 15955209 DOI: 10.1111/j.1440-1746.2005.03862.x]
85. Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther 2014;7:1015-1023 [PMID: 24959088]
86. Kim SS, Ahn CH, Kang MR, Kim YR, Kim HS, Yoo NJ, Lee SH. Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers. Pathology 2010;42:50-53 [PMID: 20025480 DOI: 10.3109/00313020903434421]
87. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang HY, Chua KF. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaBdependent gene expression and organismal life span. Cell 2009;136:62-74 [PMID: 19135889 DOI: 10.1016/j.cell.2008.10.052]
88. Yun D, Rahmani M, Dent P Grant S. Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun. N-Terminal Kinase 1 Activation. Mol Cell Biol 2005;25:1016-1024 [DOI: 10.1128/MCB.25.13.5429-5444.2005]
89. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-2380 [PMID: 15152190 DOI: 10.1038/sj.emboj.7600244]